Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia
DJ DeAngelo, BA Jonas, JL Liesveld… - Blood, The Journal …, 2022 - ashpublications.org
Abstract Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival
pathways, enhances chemotherapy response, improves survival in mouse xenograft and …
pathways, enhances chemotherapy response, improves survival in mouse xenograft and …
Methods for treating acute myeloid leukemia and related conditions
HM Thackray, HH Flanner, CD Wolfgang - US Patent 11,707,474, 2023 - Google Patents
Methods for treating or inhibiting cancer and/or one or more related conditions by
administering to a subject in need thereof an effective amount of a compound of Formula (I) …
administering to a subject in need thereof an effective amount of a compound of Formula (I) …